Companies › Context Therapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CTIM-76 CLDN6-directed T cell-engaging bispecific antibody | CLDN6 | Phase 1 | Platinum-resistant Ovarian Cancer | May 2028 |
| CT-202 Nectin-4 directed bispecific antibody engaging T cells | NECTIN4 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Jan 2030 |
| CT-95 MSLN bispecific antibody | MSLN | Phase 1 | Mesothelin-Expressing Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06756035 | CT-95 | Phase 1 | Mesothelin-Expressing Tumors | Oncology | Oct 2026 |
| NCT06515613 | CTIM-76 | Phase 1 | Platinum-resistant Ovarian Cancer | Oncology | May 2028 |
| NCT07545122 | CT-202 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Oncology | Jan 2030 |
Cash of $43m on 2026-06-30; operating cash outflow about $37m a year; runway about 14 months at that burn, to Aug 2027
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.